Magnostics is an Irish company bringing to market technology to improve the effectiveness of personalized cancer therapies and care. Many cancer patients today benefit from liquid biopsies, based on a blood sample, with the aim of detecting cancer earlier and optimizing their treatment. Currently, existing technologies recover only about 50% of the tumour DNA in blood, leading to high liquid biopsy failure rates and high costs in terms of non-optimized treatment. We can recover +90% of the tumour DNA, resulting in significantly improved outcomes.
Menu
